Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
194.38
Dollar change
+3.86
Percentage change
2.03
%
IndexNDX, S&P 500 P/E24.36 EPS (ttm)7.98 Insider Own0.80% Shs Outstand144.90M Perf Week-1.92%
Market Cap28.26B Forward P/E11.25 EPS next Y17.28 Insider Trans-0.10% Shs Float144.19M Perf Month-10.90%
Income1.16B PEG8.70 EPS next Q3.43 Inst Own90.16% Short Float2.46% Perf Quarter-22.24%
Sales9.42B P/S3.00 EPS this Y5.20% Inst Trans0.83% Short Ratio2.98 Perf Half Y-26.23%
Book/sh102.14 P/B1.90 EPS next Y11.60% ROA4.52% Short Interest3.55M Perf Year-33.85%
Cash/sh7.22 P/C26.91 EPS next 5Y2.80% ROE8.24% 52W Range189.52 - 319.76 Perf YTD-24.88%
Dividend Est.- P/FCF- EPS past 5Y-18.05% ROI5.28% 52W High-39.21% Beta0.03
Dividend TTM- Quick Ratio1.26 Sales past 5Y-4.53% Gross Margin67.84% 52W Low2.56% ATR (14)4.42
Dividend Ex-Date- Current Ratio2.00 EPS Y/Y TTM-61.76% Oper. Margin17.32% RSI (14)31.31 Volatility1.92% 1.99%
Employees7570 Debt/Eq0.50 Sales Y/Y TTM-1.56% Profit Margin12.33% Recom1.60 Target Price290.11
Option/ShortYes / Yes LT Debt/Eq0.49 EPS Q/Q-54.79% Payout0.00% Rel Volume1.34 Prev Close190.52
Sales Surprise-3.23% EPS Surprise-7.35% Sales Q/Q-7.78% EarningsApr 24 BMO Avg Volume1.19M Price194.38
SMA20-5.80% SMA50-10.46% SMA200-20.91% Trades Volume1,599,564 Change2.03%
Date Action Analyst Rating Change Price Target Change
Feb-14-24Reiterated Needham Buy $305 → $300
Feb-14-24Downgrade Wells Fargo Overweight → Equal Weight $315 → $240
Jan-24-24Downgrade UBS Buy → Neutral $311 → $276
Dec-20-23Resumed Cantor Fitzgerald Overweight $311
Dec-07-23Upgrade Raymond James Mkt Perform → Outperform $283
Sep-06-23Initiated HSBC Securities Buy $360
Jul-27-23Initiated Scotiabank Sector Outperform $327
Jul-24-23Reiterated UBS Buy $346 → $335
May-01-23Upgrade Guggenheim Neutral → Buy $270 → $350
Apr-17-23Upgrade Piper Sandler Neutral → Overweight $280 → $346
Apr-19-24 09:39AM
09:15AM
Apr-18-24 12:01PM
Apr-17-24 10:01AM
Apr-12-24 10:00AM
02:15PM Loading…
Apr-11-24 02:15PM
Apr-10-24 06:09PM
Apr-01-24 05:50PM
04:02PM
Mar-31-24 07:30PM
11:53AM
Mar-28-24 08:00AM
Mar-27-24 12:18PM
Mar-26-24 11:21AM
Mar-25-24 05:50PM
07:05AM Loading…
Mar-22-24 07:05AM
06:57AM
Mar-21-24 05:14PM
09:17AM
04:39AM
Mar-18-24 05:50PM
10:16AM
Mar-15-24 09:34AM
Mar-14-24 11:30AM
Mar-12-24 05:50PM
Mar-11-24 12:44PM
09:00AM
Mar-08-24 04:11PM
04:07PM
02:48PM
02:38PM Loading…
02:38PM
11:44AM
10:58AM
10:52AM
10:20AM
Mar-07-24 09:31AM
Mar-06-24 05:45PM
07:30AM
Mar-05-24 05:50PM
08:33AM
Mar-04-24 04:15PM
Mar-02-24 04:53AM
Mar-01-24 01:45PM
Feb-28-24 05:45PM
Feb-25-24 07:04AM
Feb-23-24 12:44PM
07:00AM
06:14AM
05:56AM
Feb-20-24 11:21AM
Feb-19-24 01:46PM
Feb-15-24 04:13PM
Feb-14-24 05:11PM
09:11AM
06:42AM
06:37AM
06:18AM
01:35AM
Feb-13-24 04:34PM
02:45PM
01:09PM
12:53PM
11:44AM
11:17AM
10:50AM
10:44AM
10:29AM
10:27AM
10:24AM
09:53AM
09:30AM
08:46AM
08:20AM
08:01AM
07:36AM
07:34AM
07:04AM
07:00AM
Feb-12-24 04:43PM
04:19PM
04:06PM
Feb-10-24 08:30AM
Feb-09-24 10:00AM
Feb-08-24 05:45PM
10:32AM
09:15AM
Feb-06-24 10:00AM
Feb-02-24 05:45PM
Feb-01-24 10:27AM
12:46AM
Jan-31-24 01:06PM
11:02AM
09:26AM
08:16AM
07:55AM
07:50AM
07:36AM
07:30AM
06:33AM
Jan-30-24 08:30AM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singhal PriyaHead of DevelopmentApr 02 '24Sale213.099319,8174,886Apr 03 08:24 PM
Murphy NicoleHead of Pharm Ops and TechApr 01 '24Option Exercise0.0024009,751Apr 03 08:11 PM
Singhal PriyaHead of DevelopmentFeb 22 '24Sale221.2326257,9624,886Feb 26 07:54 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Option Exercise0.001,20805,429Feb 21 09:27 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 16 '24Option Exercise0.005,037052,506Feb 21 09:39 PM
Gregory GingerEVP, Human ResourcesFeb 16 '24Option Exercise0.004,704014,341Feb 21 09:36 PM
Izzar RachidHead of Global Product Strat.Feb 16 '24Option Exercise0.002,017010,014Feb 21 09:33 PM
Kramer RobinChief Accounting OfficerFeb 16 '24Option Exercise0.001,34506,354Feb 21 09:31 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 16 '24Option Exercise0.006,720020,692Feb 21 09:29 PM
Murphy NicoleHead of Pharm Ops and TechFeb 16 '24Option Exercise0.001,26009,624Feb 21 09:28 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Sale221.4910823,9215,148Feb 21 09:27 PM
Rowinsky Eric KDirectorFeb 15 '24Buy222.54455101,25620,629Feb 20 09:13 PM
Singhal PriyaHead of DevelopmentFeb 12 '24Sale239.45419100,3304,516Feb 13 06:06 PM
Izzar RachidHead of Global Product Strat.Feb 09 '24Option Exercise0.001,51509,081Feb 13 06:00 PM
Singhal PriyaHead of DevelopmentFeb 09 '24Option Exercise0.001,21205,309Feb 13 06:06 PM
Murphy NicoleHead of Pharm Ops and TechFeb 09 '24Option Exercise0.002,27209,529Feb 13 06:04 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 09 '24Option Exercise0.003,257017,555Feb 13 06:03 PM
Kramer RobinChief Accounting OfficerFeb 09 '24Option Exercise0.0083305,523Feb 13 06:01 PM
Gregory GingerEVP, Human ResourcesFeb 09 '24Option Exercise0.002,158011,778Feb 13 06:14 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 09 '24Option Exercise0.002,575050,021Feb 13 05:56 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 08 '24Option Exercise0.002,335015,063Feb 09 08:03 PM
Murphy NicoleHead of Pharm Ops and TechFeb 08 '24Option Exercise0.002,10107,895Feb 09 08:01 PM
Kramer RobinChief Accounting OfficerFeb 08 '24Option Exercise0.0078804,943Feb 09 08:06 PM
Gregory GingerEVP, Human ResourcesFeb 08 '24Option Exercise0.001,635010,118Feb 09 08:14 PM
Izzar RachidHead of Global Product Strat.Feb 08 '24Option Exercise0.002,04308,187Feb 09 08:11 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 08 '24Option Exercise0.002,190048,101Feb 09 08:16 PM
Singhal PriyaHead of DevelopmentFeb 02 '24Sale245.93634155,9204,097Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentFeb 01 '24Option Exercise0.001,82805,292Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentDec 11 '23Sale248.0011027,2803,464Dec 12 05:06 PM
Kramer RobinChief Accounting OfficerDec 08 '23Option Exercise0.0035104,325Dec 12 05:02 PM
Singhal PriyaHead of DevelopmentDec 08 '23Option Exercise0.0042603,780Dec 12 05:06 PM
BIOGEN INC.10% OwnerSep 26 '23Sale0.506,000,0003,000,00017,652,466Sep 28 05:30 PM
Singhal PriyaHead of DevelopmentSep 05 '23Sale269.43431116,1243,354Sep 06 06:06 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01 '23Option Exercise0.005,285014,060Sep 06 06:08 PM
Singhal PriyaHead of DevelopmentSep 01 '23Option Exercise0.001,66804,592Sep 06 06:06 PM
Singhal PriyaHead of DevelopmentJul 03 '23Sale282.878122,9122,924Jul 05 05:33 PM
Singhal PriyaHead of DevelopmentJun 30 '23Option Exercise0.0031503,158Jul 05 05:33 PM
Izzar RachidHead of Global Product Strat.Jun 30 '23Option Exercise0.0050406,388Jul 05 05:37 PM
Kramer RobinChief Accounting OfficerJun 30 '23Option Exercise0.0025204,096Jul 05 05:35 PM
Gregory GingerEVP, Human ResourcesApr 28 '23Sale300.002,681804,3008,483May 02 08:05 PM